<article article-type="data-paper" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12901407</article-id><article-id pub-id-type="pmcid-ver">PMC12901407.1</article-id><article-id pub-id-type="pmcaid">12901407</article-id><article-id pub-id-type="pmcaiid">12901407</article-id><article-id pub-id-type="pmid">41693775</article-id><article-id pub-id-type="doi">10.3389/fphar.2026.1736083</article-id><article-id pub-id-type="publisher-id">1736083</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Data Report</subject></subj-group></article-categories><title-group><article-title>Case study on adverse reactions of dulaglutide: literature review</article-title><alt-title alt-title-type="left-running-head">Zhou and Jiang</alt-title><alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2026.1736083" xmlns:xlink="http://www.w3.org/1999/xlink">10.3389/fphar.2026.1736083</ext-link>
</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yang</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="c001">*</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="W">Weihao</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3259317" xmlns:xlink="http://www.w3.org/1999/xlink"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &amp; editing/">Writing - review and editing</role></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Department of Pharmacy, The Fifth People’s Hospital of Chengdu University of Traditional Chinese Medicine/Chengdu Fifth People’s Hospital</institution>, <city>Chengdu</city>, <country country="CN">China</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Department of Pharmacy, Chengdu Institute of Brain Science Clinical Hospital, University of Electronic Science and Technology/Chengdu Fourth People’s Hospital</institution>, <city>Chengdu</city>, <country country="CN">China</country>
</aff><author-notes><corresp id="c001">
<label>*</label>Correspondence: Yang Zhou, <email xlink:href="mailto:zy02@163.com" xmlns:xlink="http://www.w3.org/1999/xlink">zy02@163.com</email>
</corresp></author-notes><pub-date date-type="pub" iso-8601-date="2026-01-30" publication-format="electronic"><day>30</day><month>1</month><year>2026</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2026</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">506021</issue-id><elocation-id>1736083</elocation-id><history><date date-type="received"><day>30</day><month>10</month><year>2025</year></date><date date-type="rev-recd"><day>18</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>14</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-16 15:25:13.347"><day>16</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2026 Zhou and Jiang.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder>Zhou and Jiang</copyright-holder><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" start_date="2026-01-30" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="fphar-17-1736083.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><kwd-group><kwd>adverse drug reactions</kwd><kwd>case</kwd><kwd>dulaglutide</kwd><kwd>literature</kwd><kwd>medication safety</kwd></kwd-group><funding-group><funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement></funding-group><counts><fig-count count="0"/><table-count count="5"/><equation-count count="0"/><ref-count count="32"/><page-count count="7"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pharmacoepidemiology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><label>1</label><title>Introduction</title><p>Glucagon like peptide-1 receptor agonists (GLP-1 RA), as a new generation of hypoglycemic drugs, can simulate the physiological effects of GLP-1 and have multiple clinical advantages such as lowering blood sugar, weight loss, and cardiovascular benefits (<xref ref-type="bibr" rid="B4">Chinese Medical Association Diabetes Branch, 2021</xref>).</p><p>Dulaglutide belongs to GLP-1RA and was approved for marketing in China in 2019 (<xref ref-type="bibr" rid="B32">Zheng et al., 2020</xref>). Common adverse drug reactions (ADRs) are mainly gastrointestinal reactions (<xref ref-type="bibr" rid="B5">Chinese Society of Endocrinology and and Chinese Society of Diabetes, 2020</xref>). At present, there are relatively few case reports on ADR. Based on existing case reports at home and abroad, this study aims to analyze the characteristics of ADR occurrence and development related to this drug, and provide reference for safe clinical use.</p></sec><sec id="s2"><label>2</label><title>Data and methods</title><sec id="s2-1"><label>2.1</label><title>Source of information</title><p>Retrieve databases from China National Knowledge Infrastructure, Wanfang, and VIP PubMed、Web of Science. The Chinese search terms are “dulaglutide”, “adverse reactions”, and “case reports”; The English search terms are “dulaglutide”, “dulaglutide induced”, “dulaglutide related”, “adverse reaction”, and “case report”. The search period is from September 2014 to March 2025, excluding literature with unclear descriptions and duplicate cases. A total of 21 articles (<xref ref-type="bibr" rid="B19">Okiro et al., 2017</xref>; <xref ref-type="bibr" rid="B26">Taylor and Moody, 2018</xref>; <xref ref-type="bibr" rid="B10">Hamann et al., 2019</xref>; <xref ref-type="bibr" rid="B21">Rajput et al., 2018</xref>; <xref ref-type="bibr" rid="B7">Fukuda et al., 2019</xref>; <xref ref-type="bibr" rid="B20">Patel et al., 2019</xref>; <xref ref-type="bibr" rid="B16">Lee et al., 2021</xref>; <xref ref-type="bibr" rid="B18">Moore et al., 2024</xref>; <xref ref-type="bibr" rid="B22">Rzepka and Kaffenberger, 2020</xref>; <xref ref-type="bibr" rid="B12">Kalas et al., 2021</xref>; <xref ref-type="bibr" rid="B3">Butler et al., 2021</xref>; <xref ref-type="bibr" rid="B14">Kohli et al., 2021</xref>; <xref ref-type="bibr" rid="B13">Karakousis et al., 2021</xref>; <xref ref-type="bibr" rid="B15">Kyriakos et al., 2022</xref>; <xref ref-type="bibr" rid="B23">Samhani et al., 2024</xref>; <xref ref-type="bibr" rid="B25">Sonego et al., 2023</xref>; <xref ref-type="bibr" rid="B28">Vaccaro et al., 2023</xref>; <xref ref-type="bibr" rid="B2">Baker Khan et al., 2023</xref>; <xref ref-type="bibr" rid="B24">Shahbazi et al., 2023</xref>; <xref ref-type="bibr" rid="B30">Wang et al., 2023</xref>; <xref ref-type="bibr" rid="B31">Zhang et al., 2024</xref>) (involving 22 patients) were obtained that meet the criteria, including 20 English articles involving 21 patients; One Chinese literature article involving one patient.</p></sec><sec id="s2-2"><label>2.2</label><title>Methods</title><p>The basic information of each ADR case study was counted, with information on gender, age, underlying disease, dulaglutide administration, and time of ADR occurrence, clinical presentation, management and regression of all patients.</p></sec></sec><sec id="s3" sec-type="results"><label>3</label><title>Results</title><sec id="s3-1"><label>3.1</label><title>Basic information of patient</title><p>A total of 21 case studies containing 22 patients were included in this study. All of these cases were reported from 2017 to 2024, of which 10 were from the United States, 2 were from Ireland, 2 were from China, and individual cases from countries such as Denmark, France, and Greece were also included, and their basic profiles are shown in <xref ref-type="table" rid="T1">Table 1</xref>. The 22 patients included in the study consisted of 12 males and 10 females, and their underlying diseases were all diabetes mellitus, except for one case (<xref ref-type="bibr" rid="B2">Baker Khan et al., 2023</xref>), which was type 1 diabetes mellitus (T1DM) and one (<xref ref-type="bibr" rid="B31">Zhang et al., 2024</xref>) had latent autoimmune diabetes mellitus (LADA) in adults, all other patients had type 2 diabetes mellitus (T2DM). Common comorbidities in these patients included hypertension, hyperlipidemia, obesity, coronary artery disease, hyperuricemia, hyperthyroidism or disorders, chronic obstructive pulmonary disease (COPD), heart failure, coronary artery disease (CAD), and chronic obstructive pulmonary disease (COPD). The dosage of dulaglutide was 0.75 or 1.5 mg per week in all patients except for 6 (<xref ref-type="bibr" rid="B10">Hamann et al., 2019</xref>; <xref ref-type="bibr" rid="B20">Patel et al., 2019</xref>; <xref ref-type="bibr" rid="B22">Rzepka and Kaffenberger, 2020</xref>; <xref ref-type="bibr" rid="B14">Kohli et al., 2021</xref>; <xref ref-type="bibr" rid="B28">Vaccaro et al., 2023</xref>; <xref ref-type="bibr" rid="B31">Zhang et al., 2024</xref>)patients with incomplete information, 1 (<xref ref-type="bibr" rid="B3">Butler et al., 2021</xref>) patient with a dulaglutide dosing regimen of 2 mg per week and 1 (<xref ref-type="bibr" rid="B23">Samhani et al., 2024</xref>) patient with a dulaglutide dosing regimen of 3 mg per week. In addition, it is noteworthy that 4 (<xref ref-type="bibr" rid="B21">Rajput et al., 2018</xref>; <xref ref-type="bibr" rid="B23">Samhani et al., 2024</xref>; <xref ref-type="bibr" rid="B2">Baker Khan et al., 2023</xref>; <xref ref-type="bibr" rid="B24">Shahbazi et al., 2023</xref>) patients had ADRs that occurred only after the dosing dose had risen, and the original dosing dose did not contribute to the occurrence of the ADRs. The correlation between ADRs and the use of Dulaglutide in 22 patients was evaluated as “possible” according to the Measures for the Reporting and Monitoring of Adverse Drug Reactions. Most of the patients used 1-4 kinds of combination drugs, mainly hypoglycemic drugs, antihypertensive drugs, lipid regulating drugs and antiplatelet drugs. Common hypoglycemic agents are metformin, sulfonylurea hypoglycemic agents and insulin, common antihypertensive agents are amlodipine and bisoprolol, common lipid regulating agents are simvastatin and resuvastatin, and antiplatelet agents are mainly aspirin. Referring to the drug inserts of the above co-administered drugs, no significant interaction with Dulaglutide has been observed. However, maintenance or gradual reduction of insulin dose should be considered when using Dulaglutide, which may increase the risk of diabetic ketoacidosis if the dose is reduced or discontinued too rapidly. The gender and age distribution of the patients is shown in <xref ref-type="table" rid="T2">Table 2</xref>.</p><table-wrap id="T1" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Basic information of case study research.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">Serial number</th><th align="left" colspan="1" rowspan="1">Year of publication</th><th align="left" colspan="1" rowspan="1">Lead author</th><th align="left" colspan="1" rowspan="1">Country to the research results belong</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">1 (<xref ref-type="bibr" rid="B19">Okiro et al., 2017</xref>)</td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Julie Omolola Okiro</td><td align="left" colspan="1" rowspan="1">Ireland</td></tr><tr><td align="left" colspan="1" rowspan="1">2 (<xref ref-type="bibr" rid="B26">Taylor and Moody, 2018</xref>)</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Shawn R Taylor</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">3 (<xref ref-type="bibr" rid="B10">Hamann et al., 2019</xref>)</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Carsten R Hamann</td><td align="left" colspan="1" rowspan="1">Denmark</td></tr><tr><td align="left" colspan="1" rowspan="1">4 (<xref ref-type="bibr" rid="B21">Rajput et al., 2018</xref>)</td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Rajesh Rajput</td><td align="left" colspan="1" rowspan="1">India</td></tr><tr><td align="left" colspan="1" rowspan="1">5 (<xref ref-type="bibr" rid="B7">Fukuda et al., 2019</xref>)</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Gen Fukuda</td><td align="left" colspan="1" rowspan="1">Japan</td></tr><tr><td align="left" colspan="1" rowspan="1">6 (<xref ref-type="bibr" rid="B20">Patel et al., 2019</xref>)</td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Anish Vinit Patel</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">7 (<xref ref-type="bibr" rid="B16">Lee et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Jayden Lee</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">8 (<xref ref-type="bibr" rid="B18">Moore et al., 2024</xref>)</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Hannah E Moore</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">9 (<xref ref-type="bibr" rid="B22">Rzepka and Kaffenberger, 2020</xref>)</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Polina V Rzepka</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">10 (<xref ref-type="bibr" rid="B12">Kalas et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">M Ammar Kalas</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">11 (<xref ref-type="bibr" rid="B3">Butler et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Jared Butler</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">12 (<xref ref-type="bibr" rid="B14">Kohli et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Varun Kohli</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">13 (<xref ref-type="bibr" rid="B13">Karakousis et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Nikolaos Karakousis</td><td align="left" colspan="1" rowspan="1">Greece</td></tr><tr><td align="left" colspan="1" rowspan="1">14 (<xref ref-type="bibr" rid="B15">Kyriakos et al., 2022</xref>)</td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Georgios Kyriakos</td><td align="left" colspan="1" rowspan="1">Spain</td></tr><tr><td align="left" colspan="1" rowspan="1">15 (<xref ref-type="bibr" rid="B23">Samhani et al., 2024</xref>)</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">C Samhani</td><td align="left" colspan="1" rowspan="1">France</td></tr><tr><td align="left" colspan="1" rowspan="1">16 (<xref ref-type="bibr" rid="B25">Sonego et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Benedetta Sonego</td><td align="left" colspan="1" rowspan="1">Italy</td></tr><tr><td align="left" colspan="1" rowspan="1">17 (<xref ref-type="bibr" rid="B28">Vaccaro et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Christopher J Vaccaro</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">18 (<xref ref-type="bibr" rid="B2">Baker Khan et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Abu Baker Khan</td><td align="left" colspan="1" rowspan="1">Pakistan</td></tr><tr><td align="left" colspan="1" rowspan="1">19 (<xref ref-type="bibr" rid="B24">Shahbazi et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Mohammad Shahbazi</td><td align="left" colspan="1" rowspan="1">United States</td></tr><tr><td align="left" colspan="1" rowspan="1">20 (<xref ref-type="bibr" rid="B30">Wang et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">2023</td><td align="left" colspan="1" rowspan="1">Junwen Wang</td><td align="left" colspan="1" rowspan="1">China</td></tr><tr><td align="left" colspan="1" rowspan="1">21 (<xref ref-type="bibr" rid="B31">Zhang et al., 2024</xref>)</td><td align="left" colspan="1" rowspan="1">2024</td><td align="left" colspan="1" rowspan="1">Jiaming Zhang</td><td align="left" colspan="1" rowspan="1">China</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Distribution of the patients’gender and age [case (%), n = 22].</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">Age (Years old)</th><th align="left" colspan="1" rowspan="1">Male</th><th align="left" colspan="1" rowspan="1">Female</th><th align="left" colspan="1" rowspan="1">Total and percentage of the overall count</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">31–40</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">2 (9.09%)</td></tr><tr><td align="left" colspan="1" rowspan="1">41–50</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">3 (13.64%)</td></tr><tr><td align="left" colspan="1" rowspan="1">51–60</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">5 (22.73%)</td></tr><tr><td align="left" colspan="1" rowspan="1">61–70</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">5 (22.73%)</td></tr><tr><td align="left" colspan="1" rowspan="1">71–80</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">5 (22.73%)</td></tr><tr><td align="left" colspan="1" rowspan="1">80+</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2 (9.09%)</td></tr></tbody></table></table-wrap></sec><sec id="s3-2"><label>3.2</label><title>Characteristics of ADR occurrence</title><p>The vast majority of patients experienced ADR within 15 months after medication (21 cases, 95.45%), with a higher incidence within 2 months after medication (19 cases, 86.36%). It is worth noting that in 3 patients (<xref ref-type="bibr" rid="B21">Rajput et al., 2018</xref>; <xref ref-type="bibr" rid="B2">Baker Khan et al., 2023</xref>; <xref ref-type="bibr" rid="B24">Shahbazi et al., 2023</xref>), the dosage of dulaglutide increased from 0.75 mg per week to 1.5 mg per week, and in 1 patient (<xref ref-type="bibr" rid="B23">Samhani et al., 2024</xref>), it increased from 1.5 mg per week to 3 mg per week. No adverse drug reactions occurred before the dosage doubled. The occurrence time and clinical manifestations of ADR are detailed in <xref ref-type="table" rid="T3">Table 3</xref>. The organs or systems most commonly affected by ADR are the skin and its appendages (6 cases, 27.27%), the digestive system (5 cases, 22.73%), and the circulatory system (5 cases, 22.73%). The organs/systems and clinical symptoms affected by ADR are shown in <xref ref-type="table" rid="T4">Table 4</xref>.</p><table-wrap id="T3" orientation="portrait" position="float"><label>TABLE 3</label><caption><p>Types and onset of adverse drug reactions (n = 22).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">After the first dose (or after using a new treatment regimen)</th><th align="left" colspan="1" rowspan="1">Number of cases</th><th align="left" colspan="1" rowspan="1">Types of adverse drug reactions</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Within 2 months</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">Myocardial infarction (1)<break/>Acute pancreatitis (2)<break/>Vaginal bleeding (1)<break/>Allergic reactions (including one rare allergic reaction, Kounis syndrome) (2)<break/>Ketoacidosis (3)<break/>Ischemic stroke (1)<break/>Rash (2)<break/>Acute kidney injury (1)<break/>Liver injury (1)<break/>Hypoglycemia (1)<break/>Vascular edema (1)<break/>Atrial fibrillation (1)<break/>Bullous pemphigoid (1)<break/>Pyoderma gangrenosum (1)</td></tr><tr><td align="left" colspan="1" rowspan="1">2–15 months</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Bullous pemphigoid (1)<break/>Gastroparesis (1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Over 15 months</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Acute cholecystitis (1)</td></tr></tbody></table></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>TABLE 4</label><caption><p>ADR involved organs/systems and types of diseases (n = 22).</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">Affected organs/systems</th><th align="left" colspan="1" rowspan="1">Types of diseases</th><th align="left" colspan="1" rowspan="1">Number of cases (%)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Skin and its appendages</td><td align="left" colspan="1" rowspan="1">Rash (2)<break/>Bullous pemphigoid (2)<break/>Pyoderma gangrenosum (1)<break/>Allergic reactions (1)</td><td align="left" colspan="1" rowspan="1">6 (27.27%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Digestive system</td><td align="left" colspan="1" rowspan="1">Acute pancreatitis (2)<break/>Gastroparesis (1)<break/>Liver injury (1)<break/>Acute cholecystitis (1)</td><td align="left" colspan="1" rowspan="1">5 (22.73%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Circulatory system</td><td align="left" colspan="1" rowspan="1">Myocardial infarction (1)<break/>Kounis Syndrome (1)<break/>Ischemic stroke (1)<break/>Vascular edema (1)<break/>Atrial fibrillation (1)</td><td align="left" colspan="1" rowspan="1">5 (22.73%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Reproductive system</td><td align="left" colspan="1" rowspan="1">Vaginal bleeding (1)</td><td align="left" colspan="1" rowspan="1">1 (4.55%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Urinary system</td><td align="left" colspan="1" rowspan="1">Acute kidney injury (1)</td><td align="left" colspan="1" rowspan="1">1 (4.55%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Endocrine system</td><td align="left" colspan="1" rowspan="1">Hypoglycemia (1)</td><td align="left" colspan="1" rowspan="1">1 (4.55%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Others</td><td align="left" colspan="1" rowspan="1">Ketoacidosis (3)</td><td align="left" colspan="1" rowspan="1">3 (13.64%)</td></tr></tbody></table></table-wrap><p>Among all 22 patients, 21 improved after discontinuation of medication or symptomatic supportive treatment, while 1 patient (<xref ref-type="bibr" rid="B14">Kohli et al., 2021</xref>) had a poor prognosis due to severe allergic reactions and developed ischemic brain injury. The ADR observed in this patient is Kounis syndrome (<xref ref-type="bibr" rid="B11">Han et al., 2024</xref>), also known as ST segment elevation acute coronary syndrome associated with allergies. It occurs due to allergic reactions to disease, food, medication, or environmental factors, which may be accompanied by rash, urticaria, skin itching, nausea, vomiting, wheezing, and angioedema; This disease has an impact on the coronary artery system, leading to the occurrence of acute coronary syndrome. At present, the academic community’s attention and research depth on this disease are clearly insufficient. Although there are some related reports, most of them are individual case reports. The control of ADR is symptomatic treatment, such as the use of antihistamines or glucocorticoids for allergic reactions, wound drainage for severe skin infections, the use of cardiovascular disease-related drugs for circulatory system symptoms, or surgical treatment for severe cases. It should be noted that two patients did not stop using dulaglutide. One case (<xref ref-type="bibr" rid="B18">Moore et al., 2024</xref>) had hypoglycemia due to not following the weekly dosage of 1.5 mg dulaglutide as prescribed by the doctor, but instead using 1.5 mg dulaglutide daily. After following the correct doctor’s advice and reducing insulin dosage appropriately, her symptoms improved significantly. The other patient (<xref ref-type="bibr" rid="B3">Butler et al., 2021</xref>) underwent cholecystectomy to treat acute cholecystitis induced by dulaglutide. The patient continued to use dulaglutide after surgery, and there was no recurrence of gallstones or other abdominal symptoms 8 months after the initial cholecystitis event. The performance, handling, and outcome of ADR are detailed in <xref ref-type="table" rid="T5">Table 5</xref>.</p><table-wrap id="T5" orientation="portrait" position="float"><label>TABLE 5</label><caption><p>Clinical manifestation, treatments and outcomes of ADRs.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" colspan="1" rowspan="1">Serial number</th><th align="left" colspan="1" rowspan="1">Clinical manifestations</th><th align="left" colspan="1" rowspan="1">Methods of treatment</th><th align="left" colspan="1" rowspan="1">Consequence</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">1 (<xref ref-type="bibr" rid="B19">Okiro et al., 2017</xref>)</td><td align="left" colspan="1" rowspan="1">Severe dehydration, low blood pressure, hypothermia, rapid heart rate</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately with IV saline and insulin, IV ceftriaxone</td><td align="left" colspan="1" rowspan="1">Relief to discharge after 6 days</td></tr><tr><td align="left" colspan="1" rowspan="1">2 (<xref ref-type="bibr" rid="B19">Okiro et al., 2017</xref>)</td><td align="left" colspan="1" rowspan="1">mildly impaired consciousness</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately and administer saline and insulin intravenously</td><td align="left" colspan="1" rowspan="1">Relief to discharge after 4 days</td></tr><tr><td align="left" colspan="1" rowspan="1">3 (<xref ref-type="bibr" rid="B26">Taylor and Moody, 2018</xref>)</td><td align="left" colspan="1" rowspan="1">kidney damage</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately</td><td align="left" colspan="1" rowspan="1">Significant improvement on day 10</td></tr><tr><td align="left" colspan="1" rowspan="1">4 (<xref ref-type="bibr" rid="B10">Hamann et al., 2019</xref>)</td><td align="left" colspan="1" rowspan="1">Rapidly expanding, painful, erythematous nodules on the trunk</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide with adalimumab and cyclosporine</td><td align="left" colspan="1" rowspan="1">Significant improvement after 2 months</td></tr><tr><td align="left" colspan="1" rowspan="1">5 (<xref ref-type="bibr" rid="B21">Rajput et al., 2018</xref>)</td><td align="left" colspan="1" rowspan="1">Headaches and blurred vision</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately and administer mannitol and low molecular heparin intravenously. Follow up with oral oral anticoagulants and antiplatelet agents</td><td align="left" colspan="1" rowspan="1">Significant improvement after 3 months</td></tr><tr><td align="left" colspan="1" rowspan="1">6 (<xref ref-type="bibr" rid="B7">Fukuda et al., 2019</xref>)</td><td align="left" colspan="1" rowspan="1">Pruritic erythematous lesions on the scalp and forearm skin, followed by extension of the pruritic lesions to both lower extremities</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide and injection of prednisolone and minocycline</td><td align="left" colspan="1" rowspan="1">The prognosis is good</td></tr><tr><td align="left" colspan="1" rowspan="1">7 (<xref ref-type="bibr" rid="B20">Patel et al., 2019</xref>)</td><td align="left" colspan="1" rowspan="1">Darkened urine, itching, epigastric pain, decreased appetite</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately</td><td align="left" colspan="1" rowspan="1">Significant improvement after 3 months</td></tr><tr><td align="left" colspan="1" rowspan="1">8 (<xref ref-type="bibr" rid="B16">Lee et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">Severe nausea, intermittent vomiting, weakness, loss of appetite and palpitations</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide and treatment with diltiazem drip and electroconvulsive therapy</td><td align="left" colspan="1" rowspan="1">Relief to discharge after 1 day</td></tr><tr><td align="left" colspan="1" rowspan="1">9 (<xref ref-type="bibr" rid="B18">Moore et al., 2024</xref>)</td><td align="left" colspan="1" rowspan="1">hypoglycemia</td><td align="left" colspan="1" rowspan="1">Changing the frequency of dulaglutide injections to once a week and immediately discontinuing lysergic insulin and decreasing the dose of lysergic insulin</td><td align="left" colspan="1" rowspan="1">Patient’s condition improved significantly on day 18</td></tr><tr><td align="left" colspan="1" rowspan="1">10 (<xref ref-type="bibr" rid="B22">Rzepka and Kaffenberger, 2020</xref>)</td><td align="left" colspan="1" rowspan="1">Measles-like pinkish-red macules and papules all over the body</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately and use tretinoin cream application and prednisone</td><td align="left" colspan="1" rowspan="1">Rapid relief of symptoms</td></tr><tr><td align="left" colspan="1" rowspan="1">11 (<xref ref-type="bibr" rid="B12">Kalas et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">Abdominal pain, nausea, vomiting</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately</td><td align="left" colspan="1" rowspan="1">Significant improvement after 4 weeks</td></tr><tr><td align="left" colspan="1" rowspan="1">12 (<xref ref-type="bibr" rid="B3">Butler et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">Nausea, loss of appetite, progressive intensity, and pain in the right upper abdomen</td><td align="left" colspan="1" rowspan="1">Cholecystectomy (without discontinuation of dulaglutide)</td><td align="left" colspan="1" rowspan="1">Continued use of dulaglutide with no adverse effects</td></tr><tr><td align="left" colspan="1" rowspan="1">13 (<xref ref-type="bibr" rid="B14">Kohli et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">Shortness of breath with a feeling of suffocation</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide and treatment of anaphylactic reactions with steroids, diphenhydramine, and epinephrine, with advanced cardiac life support after relapse of symptoms a few days after remission</td><td align="left" colspan="1" rowspan="1">End of treatment leaves sequelae of hypoxic brain damage</td></tr><tr><td align="left" colspan="1" rowspan="1">14 (<xref ref-type="bibr" rid="B13">Karakousis et al., 2021</xref>)</td><td align="left" colspan="1" rowspan="1">Mild swelling of the neck neck with moderate hives</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately</td><td align="left" colspan="1" rowspan="1">Rapid relief of symptoms</td></tr><tr><td align="left" colspan="1" rowspan="1">15 (<xref ref-type="bibr" rid="B15">Kyriakos et al., 2022</xref>)</td><td align="left" colspan="1" rowspan="1">Rash on arms and legs</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately and use betamethasone valerate cream coated with</td><td align="left" colspan="1" rowspan="1">Significant improvement after 2 weeks</td></tr><tr><td align="left" colspan="1" rowspan="1">16 (<xref ref-type="bibr" rid="B23">Samhani et al., 2024</xref>)</td><td align="left" colspan="1" rowspan="1">Itching, erythema, maculopapular rash on the abdomen at the injection site, and sleep disturbances</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide and treatment with antihistamines</td><td align="left" colspan="1" rowspan="1">Significant improvement after 6 days</td></tr><tr><td align="left" colspan="1" rowspan="1">17 (<xref ref-type="bibr" rid="B25">Sonego et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">Mild erythematous rash progressing to maculopapular lesions</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide with prednisone and doxycycline</td><td align="left" colspan="1" rowspan="1">The prognosis is good</td></tr><tr><td align="left" colspan="1" rowspan="1">18 (<xref ref-type="bibr" rid="B28">Vaccaro et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">Vaginal bleeding, severe fatigue, shortness of breath, decreased hemoglobin</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately and discontinue aspirin</td><td align="left" colspan="1" rowspan="1">The prognosis is good</td></tr><tr><td align="left" colspan="1" rowspan="1">19 (<xref ref-type="bibr" rid="B2">baker Khan et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">Abdominal pain radiating to the back with nausea and vomiting, elevated lipase</td><td align="left" colspan="1" rowspan="1">Discontinue dulaglutide immediately and treat with painkillers</td><td align="left" colspan="1" rowspan="1">Relief to discharge after a few days</td></tr><tr><td align="left" colspan="1" rowspan="1">20 (<xref ref-type="bibr" rid="B24">Shahbazi et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">Nausea, abdominal pain with mild epigastric tenderness</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide and rehydration with fluids, as well as bisacodyl and linaclotide</td><td align="left" colspan="1" rowspan="1">Relief to discharge after 3 days</td></tr><tr><td align="left" colspan="1" rowspan="1">21 (<xref ref-type="bibr" rid="B30">Wang et al., 2023</xref>)</td><td align="left" colspan="1" rowspan="1">Nausea, severe vomiting, chest pain</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide and continuous pumping of ondansetron injection, followed by coronary balloon dilatation and intra-aortic balloon counterpulsation</td><td align="left" colspan="1" rowspan="1">Relief to discharge after 7 days</td></tr><tr><td align="left" colspan="1" rowspan="1">22 (<xref ref-type="bibr" rid="B31">Zhang et al., 2024</xref>)</td><td align="left" colspan="1" rowspan="1">Severe nausea, vomiting, fatigue, and loss of appetite; recurrence of vomiting and dyspnea after initial hospital discharge</td><td align="left" colspan="1" rowspan="1">Immediate discontinuation of dulaglutide and vasodilator therapy</td><td align="left" colspan="1" rowspan="1">Significant improvement after 3 days</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4" sec-type="discussion"><label>4</label><title>Discussions</title><sec id="s4-1"><label>4.1</label><title>Common ADR types using dulaglutide</title><p>The common ADRs in the drug instructions of Dulaglutide are gastrointestinal reactions, including nausea, vomiting, and diarrhea. In addition, there are conditions such as hypoglycemia, acute pancreatitis, increased heart rate, allergic reactions, aggravation of cholecystitis and atrial fibrillation. However, gangrenous pyoderma, measles like drug eruption, bullous pemphigoid, and the risk of liver damage associated with drugs that involve the skin are not included in their instructions and should be considered as new ADRs. Among them, gangrenous pyoderma and bullous pemphigoid have a more severe degree of occurrence and are considered as new severe ADRs.</p></sec><sec id="s4-2"><label>4.2</label><title>ADR in relation to gender, age and dose and duration of medication administration</title><p>The gender difference of the cases included in this study was not significant, and the age was more than 50 years old (17 cases, 77.27%), which is consistent with the common age of onset of T2DM. With increasing age, the body’s hepatic and renal metabolic capacity decreases, which is one of the factors for the increase in ADR. The dosage of the drug in 14 patients in this study was 0.75–1.5 mg per week, which is a routine dosage. Although a study (<xref ref-type="bibr" rid="B29">Van et al., 2021</xref>) found no significant difference in the incidence of ADRs in patients after using dulaglutide at high doses (3.0 mg and 4.5 mg per week) compared to 1.5 mg per week, it is still recommended to use it according to the drug’s instructions and should not arbitrarily increase the dose. The results of this study showed that the time span of ADR occurrence of dulaglutide was relatively large, with an extreme value gap of more than 15 months. Therefore, it is important to closely monitor patients when starting Dulaglutide.</p></sec><sec id="s4-3"><label>4.3</label><title>ADR accumulation system and clinical presentation</title><p>Skin and adnexa: It has been shown that dipeptidyl peptidase-4 (DPP-4) inhibitors are correlated with herpetic pemphigoid (<xref ref-type="bibr" rid="B1">Arai et al., 2018</xref>), and GLP-1RA may also damage the skin due to the expression of the GLP-1 receptor in cutaneous fibroblasts and keratin-forming cells (<xref ref-type="bibr" rid="B8">Gether et al., 2019</xref>). Therefore, GLP-1RA and DPP-4 inhibitors may have similar mechanisms for causing skin and adnexal damage, and it is recommended that patients should be specifically asked in detail about their past drug history and allergy history before administration. Circulatory system: GLP-1 receptors are found in the human pancreas, intestine and heart (<xref ref-type="bibr" rid="B27">Thompson and Trujillo, 2015</xref>). Animal experiments have shown that activation of GLP-1 receptors in the autonomic nervous system enhances the activity of the sympathetic nervous system and attenuates the activity of the parasympathetic nervous system. It has been suggested that overactivation of myocardial GLP-1 receptors may increase the risk of exacerbation of atrial fibrillation in patients with paroxysmal atrial fibrillation (<xref ref-type="bibr" rid="B17">Luo et al., 2020</xref>). In addition, regarding the formation of cerebral venous thrombosis may be related to dehydration due to nausea and vomiting in patients. Although the incidence of circulatory ADRs with dulaglutide is low, it still needs to be emphasized and should be used with caution in patients with previous arrhythmias. Digestive system: Gastrointestinal reactions are the most common type of ADR with Dulaglutide. According to a survey in China, gastrointestinal reactions were most pronounced in the first 2 weeks of treatment (<xref ref-type="bibr" rid="B9">Guo et al., 2020</xref>), and the dulaglutide drug insert also mentions a cumulative 104-week reported incidence of gastrointestinal adverse events when dulaglutide 0.75 mg and 1.5 mg were used weekly, respectively, including nausea (12.9% and 21.2%), diarrhea (10.7% and 13.7%), and vomiting (6.9% and 11.5%), mostly mild or moderate, so patients need to be evaluated for gastrointestinal disorders prior to administration. In addition, the drug delays gastric emptying and prolongs gallbladder contraction, which may increase the risk of gallbladder-related disorders.</p></sec><sec id="s4-4"><label>4.4</label><title>Recommendations for pharmacovigilance of GLP-1RA analogs</title><p>An adverse reaction signal mining study based on the OpenFDA database (<xref ref-type="bibr" rid="B6">Dong and Wang, 2022</xref>) showed that GLP-1RA analogs were highly associated with ADRs such as pancreatitis, cholelithiasis, hypoglycemia, dizziness, urticaria, and injection site reactions. Liraglutide and exenatide had a higher incidence of digestive ADRs compared to dulaglutide. In addition, liraglutide had the highest incidence of acute kidney injury, exenatide had the highest incidence of hypoglycemia, and the use of dulaglutide was associated with a lower probability of ADRs involving the gastrointestinal, urinary, and endocrine systems compared with the former two. However, dulaglutide and exenatide were more prone to injection site reactions, such as localized augmentation and inflammation, compared to other types of GLP-1RAs. Taking into account the cases collected in this study and the actual clinical application, it is recommended that medical personnel start using dulaglutide at a small dose, pay attention to the patients’ previous drug history and allergy history before use, and promptly deal with ADRs when they are detected. Usually, patients with hepatic impairment do not need to adjust the dosage, but the monitoring of hepatic and renal functions should be strengthened during the use of the drug. In addition, the drug should be used with caution in patients with previous cardiac arrhythmias and acute and chronic renal impairment. If pancreatitis is suspected, it should be discontinued gradually. Dulaglutide should not be reused in patients with pancreatitis.</p></sec></sec><sec id="s5" sec-type="conclusion"><label>5</label><title>Conclusion</title><p>To sum up, dulaglutide, as a new hypoglycemic drug, provides a new choice for the treatment of diabetes, but its ADR cannot be ignored. The ADR caused by dulaglutide included in this study involves multiple systems, and some ADRs are not included in its drug instructions. With the widespread use of the drug, there may be more unknown ADRs. Medical staff need to continuously strengthen their understanding of dulaglutide ADR, especially in strengthening medication monitoring for patients with multiple comorbidities. Meanwhile, further research is needed on the mechanism of ADR of dulaglutide.</p></sec></body><back><fn-group><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/875450/overview" xmlns:xlink="http://www.w3.org/1999/xlink">Daniele Maria-Ferreira</ext-link>, Instituto de Pesquisa Pelé Pequeno Príncipe, Brazil</p></fn><fn fn-type="reviewed-by"><p>
<bold>Reviewed by:</bold>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3275033/overview" xmlns:xlink="http://www.w3.org/1999/xlink">Clément Larose</ext-link>, Laval University, Canada</p><p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3282236/overview" xmlns:xlink="http://www.w3.org/1999/xlink">Amita Sutaria</ext-link>, B.J. Medical College and Civil hospital, India</p></fn></fn-group><sec id="s6" sec-type="data-availability"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec id="s7" sec-type="ethics-statement"><title>Ethics statement</title><p>Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and the institutional requirements. The manuscript presents research on animals that do not require ethical approval for their study. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article because All cases are from published major literature.</p></sec><sec id="s8" sec-type="author-contributions"><title>Author contributions</title><p>YZ: Writing – review and editing, Writing – original draft. WJ: Writing – review and editing.</p></sec><sec id="s10" sec-type="COI-statement"><title>Conflict of interest</title><p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec id="s11" sec-type="ai-statement"><title>Generative AI statement</title><p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec id="s12" sec-type="disclaimer"><title>Publisher’s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Arai</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Shirakawa</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Konishi</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Sagawa</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Terauchi</surname><given-names>Y.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database</article-title>. <source>Diabetes Care</source>
<volume>41</volume> (<issue>9</issue>), <fpage>e130</fpage>–<lpage>e132</lpage>. <pub-id pub-id-type="doi">10.2337/dc18-0210</pub-id>
<pub-id pub-id-type="pmid">30002201</pub-id>
</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>baker Khan</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Shah</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Khan</surname><given-names>M. I.</given-names></name>
<name name-style="western"><surname>Amir</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Amir</surname><given-names>A.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Dulaglutide (trulicity)-induced acute pancreatitis: a case report</article-title>. <source>Cureus</source>
<volume>15</volume> (<issue>5</issue>), <fpage>e38630</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.38630</pub-id>
<pub-id pub-id-type="pmid">37284401</pub-id>
<pub-id pub-id-type="pmcid">PMC10241188</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Butler</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Bjurstrom</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Marceau</surname><given-names>A.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy</article-title>. <source>Am. J. Health Syst. Pharm.</source>
<volume>78</volume> (<issue>8</issue>), <fpage>684</fpage>–<lpage>688</lpage>. <pub-id pub-id-type="doi">10.1093/ajhp/zxab045</pub-id>
<pub-id pub-id-type="pmid">33594405</pub-id>
<pub-id pub-id-type="pmcid">PMC7929465</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal">
<collab>Chinese Medical Association Diabetes Branch</collab> (<year>2021</year>). <article-title>Guidelines for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)</article-title>. <source>Chin. J. Diabetes</source>
<volume>13</volume> (<issue>4</issue>), <fpage>315</fpage>–<lpage>409</lpage>.</mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal">
<collab>Chinese Society of Endocrinology, and Chinese Society of Diabetes</collab> (<year>2020</year>). <article-title>Clinical expert consensus on the use of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes mellitus</article-title>. <source>Chin. J. Intern Med.</source>
<volume>59</volume> (<issue>11</issue>), <fpage>836</fpage>–<lpage>846</lpage>.<pub-id assigning-authority="pmc" pub-id-type="doi">10.3760/cma.j.cn112138-20200704-00646</pub-id><pub-id pub-id-type="pmid">33120487</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dong</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
</person-group> (<year>2022</year>). <article-title>Mining and analysis of adverse reaction signals of glucagon like peptide-1 receptor agonists based on open FDA database</article-title>. <source>Chin. Pharm.</source>
<volume>33</volume> (<issue>12</issue>), <fpage>1485</fpage>–<lpage>1491</lpage>. <pub-id pub-id-type="doi">10.6039/j.issn.1001-0408.2022.12.13</pub-id>
</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Fukuda</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Hirayama</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Umezawa</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Takemoto</surname><given-names>M.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: a case report</article-title>. <source>Geriatr. Gerontol. Int.</source>
<volume>19</volume> (<issue>12</issue>), <fpage>1289</fpage>–<lpage>1290</lpage>. <pub-id pub-id-type="doi">10.1111/ggi.13799</pub-id>
<pub-id pub-id-type="pmid">31823494</pub-id>
</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gether</surname><given-names>I. M.</given-names></name>
<name name-style="western"><surname>Nexøe-Larsen</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Knop</surname><given-names>F. K.</given-names></name>
</person-group> (<year>2019</year>). <article-title>New avenues in the regulation of gallbladder motility—implications for the use of glucagon-like peptide-derived drugs</article-title>. <source>J. Clin. Endocrinol. Metab.</source>
<volume>104</volume> (<issue>7</issue>), <fpage>2463</fpage>–<lpage>2472</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2018-01008</pub-id>
<pub-id pub-id-type="pmid">30137354</pub-id>
</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Evaluation of characteristics of gastrointestinal adverse events with once-weekly dulaglutide treatment in Chinese patients with type 2 diabetes: a post hoc pooled analysis of two randomized trials</article-title>. <source>Diabetes Ther.</source>
<volume>11</volume> (<issue>8</issue>), <fpage>1821</fpage>–<lpage>1833</lpage>. <pub-id pub-id-type="doi">10.1007/s13300-020-00869-z</pub-id>
<pub-id pub-id-type="pmid">32621083</pub-id>
<pub-id pub-id-type="pmcid">PMC7376772</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hamann</surname><given-names>C. R.</given-names></name>
<name name-style="western"><surname>Chung</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Kaffenberger</surname><given-names>B. H.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Pyoderma gangrenosum associated with dulaglutide therapy</article-title>. <source>Int. J. Dermatol.</source>
<volume>58</volume> (<issue>10</issue>), <fpage>1202</fpage>–<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1111/ijd.14272</pub-id>
<pub-id pub-id-type="pmid">30345551</pub-id>
</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Han</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Niu</surname><given-names>D.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Progress in the study of kunis syndrome</article-title>. <source>Adv. Cardiovasc. Dis.</source>
<volume>45</volume> (<issue>04</issue>), <fpage>332</fpage>–<lpage>335</lpage>.</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kalas</surname><given-names>M. A.</given-names></name>
<name name-style="western"><surname>Galura</surname><given-names>G. M.</given-names></name>
<name name-style="western"><surname>Mccallum</surname><given-names>R. W.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Medication-induced gastroparesis: a case report</article-title>. <source>J. Investig. Med. High. Impact Case Rep.</source>
<volume>9</volume>, <fpage>23247096211051919</fpage>. <pub-id pub-id-type="doi">10.1177/23247096211051919</pub-id>
<pub-id pub-id-type="pmid">34663102</pub-id>
<pub-id pub-id-type="pmcid">PMC8529310</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Karakousis</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Kostakopoulos</surname><given-names>N. A.</given-names></name>
<name name-style="western"><surname>Georgakopoulou</surname><given-names>V. E.</given-names></name>
<name name-style="western"><surname>Pyrgioti</surname><given-names>E. E.</given-names></name>
<name name-style="western"><surname>Georgakopoulos</surname><given-names>P. N.</given-names></name>
</person-group> (<year>2021</year>). <article-title>A rare case of dulaglutide-associated angioedema in a male patient</article-title>. <source>Cureus</source>
<volume>13</volume> (<issue>11</issue>), <fpage>e20041</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.20041</pub-id>
<pub-id pub-id-type="pmid">34987924</pub-id>
<pub-id pub-id-type="pmcid">PMC8717822</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kohli</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Saba</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Sonti</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Kahloon</surname><given-names>R.</given-names></name>
</person-group> (<year>2021</year>). <article-title>TYPE II kounis syndrome in a patient with anaphylaxis to dulaglutide</article-title>. <source>J. Am. Coll. Cardiol.</source>
<volume>77</volume> (<issue>18_Suppl. ment_1</issue>), <fpage>2557</fpage>. <pub-id pub-id-type="doi">10.1016/S0735-1097(21)03912-7</pub-id>
</mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Kyriakos</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Diamantis</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Memi</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Elefsiniotis</surname><given-names>I.</given-names></name>
</person-group> (<year>2022</year>). <article-title>An uncommon case of dulaglutide-related morbilliform drug eruption</article-title>. <source>Cureus</source>
<volume>14</volume> (<issue>1</issue>), <fpage>e21536</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.21536</pub-id>
<pub-id pub-id-type="pmid">35223310</pub-id>
<pub-id pub-id-type="pmcid">PMC8864188</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Umana</surname><given-names>I. E.</given-names></name>
<name name-style="western"><surname>Nguyen</surname><given-names>J.</given-names></name>
</person-group> (<year>2021</year>). <article-title>Exacerbation of atrial fibrillation related to dulaglutide use</article-title>. <source>Clin. Case Rep.</source>
<volume>9</volume> (<issue>5</issue>), <fpage>e04223</fpage>. <pub-id pub-id-type="doi">10.1002/ccr3.4223</pub-id>
<pub-id pub-id-type="pmid">34026191</pub-id>
<pub-id pub-id-type="pmcid">PMC8123549</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Feldman</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Rothenberger</surname><given-names>S. D.</given-names></name>
<name name-style="western"><surname>Hernandez</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Gellad</surname><given-names>W. F.</given-names></name>
</person-group> (<year>2020</year>). <article-title>Coverage, formulary restrictions, and out-of-pocket costs for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in the medicare part D program</article-title>. <source>JAMA Netw. Open</source>
<volume>3</volume> (<issue>10</issue>), <fpage>e2020969</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.20969</pub-id>
<pub-id pub-id-type="pmid">33057641</pub-id>
<pub-id pub-id-type="pmcid">PMC7563069</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Moore</surname><given-names>H. E.</given-names></name>
<name name-style="western"><surname>Zaya</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Burns</surname><given-names>C. V.</given-names></name>
<name name-style="western"><surname>Berlie</surname><given-names>H. D.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Accidental once-daily use of dulaglutide: a case report</article-title>. <source>Clin. Diabetes</source>
<volume>42</volume> (<issue>3</issue>), <fpage>454</fpage>–<lpage>457</lpage>. <pub-id pub-id-type="doi">10.2337/cd23-0035</pub-id>
<pub-id pub-id-type="pmid">39015162</pub-id>
<pub-id pub-id-type="pmcid">PMC11247031</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Okiro</surname><given-names>J. O.</given-names></name>
<name name-style="western"><surname>Mc Huhg</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Abdalla</surname><given-names>A.</given-names></name>
</person-group> (<year>2017</year>). <article-title>Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists?</article-title>
<source>BMJ Case Rep.</source>
<volume>2017</volume>. <comment>bcr-2017-220437</comment>. <pub-id pub-id-type="doi">10.1136/bcr-2017-220437</pub-id>
<pub-id pub-id-type="pmcid">PMC5534999</pub-id><pub-id pub-id-type="pmid">28710307</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Patel</surname><given-names>A. V.</given-names></name>
<name name-style="western"><surname>Jotwani</surname><given-names>P. M.</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>T. P.</given-names></name>
</person-group> (<year>2019</year>). <article-title>Drug-induced liver injury due to dulaglutide use</article-title>. <source>Am. J. Ther.</source>
<volume>26</volume> (<issue>5</issue>), <fpage>e620</fpage>–<lpage>e622</lpage>. <pub-id pub-id-type="doi">10.1097/MJT.0000000000000826</pub-id>
<pub-id pub-id-type="pmid">30870146</pub-id>
</mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rajput</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Pathak</surname><given-names>V.</given-names></name>
<name name-style="western"><surname>Yadav</surname><given-names>P. K.</given-names></name>
<name name-style="western"><surname>Mishra</surname><given-names>S.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Dulaglutide-induced cerebral venous thrombosis in a patient with type 2 diabetes mellitus</article-title>. <source>BMJ Case Rep.</source>
<volume>2018</volume>, <fpage>bcr2018226346</fpage>. <pub-id pub-id-type="doi">10.1136/bcr-2018-226346</pub-id>
<pub-id pub-id-type="pmid">30413453</pub-id>
<pub-id pub-id-type="pmcid">PMC6229099</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rzepka</surname><given-names>P. V.</given-names></name>
<name name-style="western"><surname>Kaffenberger</surname><given-names>J. A.</given-names></name>
</person-group> (<year>2020</year>). <article-title>A case of morbilliform drug eruption to dulaglutide</article-title>. <source>J. Clin. Aesthet. Dermatol.</source>
<volume>13</volume> (<issue>4</issue>), <fpage>13</fpage>.
<pub-id pub-id-type="pmid">33144906</pub-id>
<pub-id pub-id-type="pmcid">PMC7605389</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Samhani</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Guerci</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Larose</surname><given-names>C.</given-names></name>
</person-group> (<year>2024</year>). <article-title>Cutaneous hypersensitivity reaction to dulaglutide: a case report of an allergic reaction</article-title>. <source>Diabetes Metab.</source>
<volume>50</volume> (<issue>5</issue>), <fpage>101552</fpage>. <pub-id pub-id-type="doi">10.1016/j.diabet.2024.101552</pub-id>
<pub-id pub-id-type="pmid">38942076</pub-id>
</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shahbazi</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Qudsiya</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Fahel</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Amini</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Tanoli</surname><given-names>T.</given-names></name>
</person-group> (<year>2023</year>). <article-title>First reported case of dulaglutide-induced acute pancreatitis with normal serum lipase level</article-title>. <source>Cureus</source>
<volume>15</volume> (<issue>6</issue>), <fpage>e40576</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.40576</pub-id>
<pub-id pub-id-type="pmid">37465801</pub-id>
<pub-id pub-id-type="pmcid">PMC10351928</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sonego</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Zelin</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Zalaudek</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>di Meo</surname><given-names>N.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature</article-title>. <source>Dermatol. Rep.</source>
<volume>15</volume> (<issue>3</issue>), <fpage>9676</fpage>. <pub-id pub-id-type="doi">10.4081/dr.2023.9676</pub-id>
<pub-id pub-id-type="pmid">37822982</pub-id>
<pub-id pub-id-type="pmcid">PMC10563024</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Taylor</surname><given-names>S. R.</given-names></name>
<name name-style="western"><surname>Moody</surname><given-names>M. T.</given-names></name>
</person-group> (<year>2018</year>). <article-title>Acute kidney injury occurring in a patient initiated on dulaglutide</article-title>. <source>J. Pharm. Technol.</source>
<volume>34</volume> (<issue>5</issue>), <fpage>231</fpage>–<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1177/8755122518782155</pub-id>
<pub-id pub-id-type="pmid">34861012</pub-id>
<pub-id pub-id-type="pmcid">PMC6109865</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Thompson</surname><given-names>A. M.</given-names></name>
<name name-style="western"><surname>Trujillo</surname><given-names>J. M.</given-names></name>
</person-group> (<year>2015</year>). <article-title>Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes</article-title>. <source>Ann. Pharmacother.</source>
<volume>49</volume> (<issue>3</issue>), <fpage>351</fpage>–<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1177/1060028014564180</pub-id>
<pub-id pub-id-type="pmid">25565404</pub-id>
</mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vaccaro</surname><given-names>C. J.</given-names></name>
<name name-style="western"><surname>Zaidi</surname><given-names>S. M. H.</given-names></name>
<name name-style="western"><surname>Iskander</surname><given-names>P. A.</given-names></name>
<name name-style="western"><surname>McFadden</surname><given-names>E.</given-names></name>
</person-group> (<year>2023</year>). <article-title>A case of dulaglutide-induced vaginal bleed</article-title>. <source>Cureus</source>
<volume>15</volume> (<issue>5</issue>), <fpage>e38774</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.38774</pub-id>
<pub-id pub-id-type="pmid">37303364</pub-id>
<pub-id pub-id-type="pmcid">PMC10249759</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Van</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Frias</surname><given-names>J. P.</given-names></name>
<name name-style="western"><surname>Bonora</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Raha</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Meyer</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Jung</surname><given-names>H.</given-names></name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Gastrointestinal tolerability of once-weekly dulaglutide 3.0 mg and 4.5 mg: a post hoc analysis of the incidence and prevalence of nausea, vomiting, and diarrhea in AWARD-11</article-title>. <source>Diabetes Ther.</source>
<volume>12</volume> (<issue>10</issue>), <fpage>2783</fpage>–<lpage>2794</lpage>. <pub-id pub-id-type="doi">10.1007/s13300-021-01140-9</pub-id>
<pub-id pub-id-type="pmid">34514554</pub-id>
<pub-id pub-id-type="pmcid">PMC8479017</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Dai</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name>
</person-group> (<year>2023</year>). <article-title>Dulaglutide-associated myocardial infarction in a case</article-title>. <source>China Mod. Appl. Pharmacol.</source>
<volume>40</volume> (<issue>10</issue>), <fpage>1390</fpage>–<lpage>1391</lpage>.</mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Zu</surname><given-names>Q.</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group> (<year>2024</year>). <article-title>GLP-1 receptor agonist-induced diabetic ketoacidosis: a case report</article-title>. <source>Med. Baltim.</source>
<volume>103</volume> (<issue>39</issue>), <fpage>e39799</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000039799</pub-id>
<pub-id pub-id-type="pmid">39331877</pub-id>
<pub-id pub-id-type="pmcid">PMC11441871</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name>
<name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Progress of clinical research on dulaglutide in the treatment of type 2 diabetes mellitus</article-title>. <source>Mod. Drugs Clin.</source>
<volume>35</volume> (<issue>1</issue>), <fpage>184</fpage>–<lpage>188</lpage>.</mixed-citation></ref></ref-list></back></article>